GlassScriptPhysician profile
Carrie Consalvi
NPI 1952743841
$464.15
in general payments reported to CMS, 2019-2025
12 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.82 · 2023: $32.27 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.03 | 2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $73.04 | 2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $44.92 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.50 | 2025 | Jardiance |
| Novo Nordisk INC | $33.16 | 2025 | Wegovy |
| Astellas Pharma US INC | $32.27 | 2023 | Myrbetriq |
| Actelion Pharmaceuticals US, INC. | $31.80 | 2025 | Opsumit |
| Abbvie INC. | $30.12 | 2022 | |
| Chiesi USA, INC. | $26.50 | 2025 | Juxtapid |
| Amgen INC. | $26.04 | 2025 | Repatha |
| Abbott Laboratories | $24.07 | 2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $21.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Consalvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.